Anatomy-based, patient-specific VMAT QA using EPID or MLC log files

Quality assurance for mixed electron-photon beam radiation therapy using treatment log files and MapCHECK

BACKGROUND

Mixed photon-electron beam radiotherapy (MBRT) is a technique that combines the use of both photons and electrons in one single treatment plan to exploit their advantageous and complimentary characteristics. Compared to other photon treatment modalities, it has been shown that the MBRT technique contributes to better target coverage and organ-at-risk (OAR) sparing. However, the use of combined photons and electrons in one delivery makes the technique more complex and a well-established quality assurance (QA) protocol for MBRT is essential.

PURPOSE

To investigate the feasibility of using MapCHECK and log file-dose reconstruction for MBRT plan verification and to recommend a patient-specific quality assurance (PSQA) protocol for MBRT.

METHODS

MBRT plans were robustly optimized for five soft-tissue sarcoma (STS) patients. Each plan comprised step-and-shoot deliveries of a six MV photon beam and a combination of five electron beam energies at an SAD of 100 cm. The plans were delivered to the MapCHECK device with collapsed gantry angle and the 2D dose distributions at the detector depth were measured. To simulate the expected dose distribution delivered to the MapCHECK, a MapCHECK computational phantom was modeled in EGSnrc based on vendor-supplied blueprint information. The dose to the detectors in the model was scored using the DOSXYZnrc user code. The agreement between the measured and the simulated dose distribution was evaluated using 2D gamma analysis with a gamma criterion of 3%/2 mm and a low dose threshold of 10%. One of the plans was selected and delivered with a rotating gantry angle for trajectory log file collection. To evaluate the potential interlinac and intralinac differences, the plan was delivered repeatedly on three linacs. From the collected log files, delivery parameters were retrieved to recalculate the 3D dose distributions in the patient's anatomy with DOSXYZnrc. The recalculated mean dose to the clinical target volume (CTV) and OARs from all deliveries were computed and compared with the planned dose in terms of percentage difference. To validate the accuracy of log file-based QA, the log file-recalculated dose was also compared with film measurement.

RESULTS

The agreement of the total dose distribution between the MapCHECK measurement and simulation showed gamma passing rates of above 97% for all five MBRT plans. In the log file-dose recalculation, the difference between the recalculated and the planned dose to the CTV and OARs was below 1% for all deliveries. No significant inter- or intralinac differences were observed. The log file-dose had a gamma passing rate of 98.6% compared to film measurement.

CONCLUSION

Both the MapCHECK measurements and log file-dose recalculations showed excellent agreement with the expected dose distribution. This study demonstrates the potential of using MapCHECK and log files as MBRT QA tools.

Deep Hybrid Learning Prediction of Patient-Specific Quality Assurance in Radiotherapy: Implementation in Clinical Routine

BACKGROUND

Arc therapy allows for better dose deposition conformation, but the radiotherapy plans (RT plans) are more complex, requiring patient-specific pre-treatment quality assurance (QA). In turn, pre-treatment QA adds to the workload. The objective of this study was to develop a predictive model of Delta4-QA results based on RT-plan complexity indices to reduce QA workload.

METHODS

Six complexity indices were extracted from 1632 RT VMAT plans. A machine learning (ML) model was developed for classification purpose (two classes: compliance with the QA plan or not). For more complex locations (breast, pelvis and head and neck), innovative deep hybrid learning (DHL) was trained to achieve better performance.

RESULTS

For not complex RT plans (with brain and thorax tumor locations), the ML model achieved 100% specificity and 98.9% sensitivity. However, for more complex RT plans, specificity falls to 87%. For these complex RT plans, an innovative QA classification method using DHL was developed and achieved a sensitivity of 100% and a specificity of 97.72%.

CONCLUSIONS

The ML and DHL models predicted QA results with a high degree of accuracy. Our predictive QA online platform is offering substantial time savings in terms of accelerator occupancy and working time.

A method for patient-specific DVH verification using a high-sampling-rate log file in an Elekta linac

We have proposed a method for patient-specific dose-volume histogram (DVH) verification using a 40-ms high-sampling-rate log file (HLF) available in an Elekta linac. Ten prostate volumetric-modulated arc therapy plans were randomly selected, and systematic leaf position errors of ±0.2, ±0.4, or ±0.8 mm were added to the 10 plans, thereby producing a total of 70 plans. An RTP file was created by interpolating each leaf position in the HLF to obtain values at each control point, which is subsequently exported to a treatment planning system. The isocenter dose calculated by the HLF-based plan to a phantom (Delta4 Phantom+) was compared to that measured by the diode in the phantom in order to evaluate the accuracy of the HLF-based dose calculation. The D95 of the planning target volume (PTV) was also compared between the HLF-based plans and the original plans with the systematic leaf position errors, the latter being referred to as theory-based plans. Sensitivities of the DVH parameters in the target, the rectum, and the bladder were also calculated with the varied systematic leaf position errors. The relative differences in the isocenter doses between the HLF-based calculations and the measurements among the 70 plans were 0.21% ± 0.67% (SD). The maximum relative differences in PTV D95 between the HLF-based and the theory-based plans among the 70 cases were 0.11%. The patient-specific DVH verification method detected a change in the target DVH parameters of less than 1% when the systematic leaf position error was ±0.2 mm. It is therefore suggested that the proposed DVH verification method may simplify patient-specific dose quality assurance procedures without compromising accuracy and sensitivity.

Spot delivery error predictions for intensity modulated proton therapy using robustness analysis with machine learning

The purpose of this work is to assess the robustness of treatment plans when spot delivery errors were predicted with a machine learning (ML) model for intensity modulated proton therapy (IMPT). Over 6000 machine log files from delivered IMPT treatment plans were included in this study. From these log files, over 4.1  × $ \times \ $ 10⁶ delivered proton spots were used to train the ML model. The presented model was tested and used to predict the spot position as well as the monitor units (MU) per spot, based on the original planning parameters. Two patient plans (one accelerated partial breast irradiation [APBI] and one ependymoma) were recalculated with the predicted spot position/MUs by the ML model and then were re-analyzed for robustness. Plans with ML predicted spots were less robust than the original clinical plans. In the APBI plan, dosimetric changes to the left lung and heart were not clinically relevant. In the ependymoma plan, the hot spot in the brainstem decreased and the hot spot in the cervical cord increased. Despite these differences, after robustness analysis, both ML spot delivery error plans resulted in >95% of the CTV receiving >95% of the prescription dose. The presented workflow has the potential benefit of including realistic spots information for plan quality checks in IMPT. This work demonstrates that in the two example plans, the plans were still robust when accounting for spot delivery errors as predicted by the ML model.

Assessment of a Therapeutic X-ray Radiation Dose Measurement System Based on a Flexible Copper Indium Gallium Selenide Solar Cell

Several detectors have been developed to measure radiation doses during radiotherapy. However, most detectors are not flexible. Consequently, the airgaps between the patient surface and detector could reduce the measurement accuracy. Thus, this study proposes a dose measurement system based on a flexible copper indium gallium selenide (CIGS) solar cell. Our system comprises a customized CIGS solar cell (with a size 10 × 10 cm2 and thickness 0.33 mm), voltage amplifier, data acquisition module, and laptop with in-house software. In the study, the dosimetric characteristics, such as dose linearity, dose rate independence, energy independence, and field size output, of the dose measurement system in therapeutic X-ray radiation were quantified. For dose linearity, the slope of the linear fitted curve and the R-square value were 1.00 and 0.9999, respectively. The differences in the measured signals according to changes in the dose rates and photon energies were <2% and <3%, respectively. The field size output measured using our system exhibited a substantial increase as the field size increased, contrary to that measured using the ion chamber/film. Our findings demonstrate that our system has good dosimetric characteristics as a flexible in vivo dosimeter. Furthermore, the size and shape of the solar cell can be easily customized, which is an advantage over other flexible dosimeters based on an a-Si solar cell.

Insensitivity of machine log files to MLC leaf backlash and effect of MLC backlash on clinical dynamic MLC motion: An experimental investigation

Purpose

Multi‐leaf‐collimator (MLC) leaf position accuracy is important for accurate dynamic radiotherapy treatment plan delivery. Machine log files have become widely utilized for quality assurance (QA) of such dynamic treatments. The primary aim is to test the sensitivity of machine log files in comparison to electronic portal imaging device (EPID)‐based measurements to MLC position errors caused by leaf backlash. The secondary aim is to investigate the effect of MLC leaf backlash on MLC leaf motion during clinical dynamic plan delivery.

Methods

The sensitivity of machine log files and two EPID‐based measurements were assessed via a controlled experiment, whereby the length of the “T” section of a series of 12 MLC leaf T‐nuts in a Varian Millennium MLC for a Trilogy C‐series type linac was reduced by sandpapering the top of the “T” to introduce backlash. The built‐in machine MLC leaf backlash test as well as measurements for two EPID‐based dynamic MLC positional tests along with log files were recorded pre‐ and post‐T‐nut modification. All methods were investigated for sensitivity to the T‐nut change by assessing the effect on measured MLC leaf positions. A reduced version of the experiment was repeated on a TrueBeam type linac with Millennium MLC.

Results

No significant differences before and after T‐nut modification were detected in any of the log file data. Both EPID methods demonstrated sensitivity to the introduced change at approximately the expected magnitude with a strong dependence observed with gantry angle. EPID‐based data showed MLC positional error in agreement with the micrometer measured T‐nut length change to 0.07 ± 0.05 mm (1 SD) using the departmental routine QA test. Backlash results were consistent between linac types.

Conclusion

Machine log files appear insensitive to MLC position errors caused by MLC leaf backlash introduced via the T‐nut. The effect of backlash on clinical MLC motions is heavily gantry angle dependent.

Retrospective analysis of portal dosimetry pre-treatment quality assurance of intracranial SRS/SRT VMAT treatment plans

Background:

The complexity associated with the treatment planning and delivery of stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT) volumetric modulated arc therapy (VMAT) plans which employs continuous dynamic modulation of dose rate, field aperture and gantry speed necessitates diligent pre-treatment patient-specific quality assurance (QA). Numerous techniques for pre-treatment VMAT treatment plans QA are currently available with the aid of several different devices including the electronic portal imager (EPID). Although several studies have provided recommendations for gamma criteria for VMAT pre-treatment QA, there are no specifics for SRS/SRT VMAT QA. Thus, we conducted a study to evaluate intracranial SRS/SRT VMAT QA to determine clinical action levels for gamma criteria based on the institutional estimated means and standard deviations.

Materials and methods:

We conducted a retrospective analysis of 118 EPID patient-specific pre-treatment QA dosimetric measurements of 47 brain SRS/SRT VMAT treatment plans using the integrated Varian solution (RapidArcTM planning, EPID and Portal dosimetry system) for planning, delivery and EPID QA analysis. We evaluated the maximum gamma (γmax), average gamma (γave) and percentage gamma passing rate (%GP) for different distance-to-agreement/dose difference (DTA/DD) criteria and low-dose thresholds.

Results:

The gamma index analysis shows that for patient-specific SRS/SRT VMAT QA with the portal dosimetry, the mean %GP is ≥98% for 2–3 mm/1–3% and Field+0%, +5% and +10% low-dose thresholds. When applying stricter spatial criteria of 1 mm, the mean %GP is >90% for DD of 2–3% and ≥88% for DD of 1%. The mean γmax ranges: 1·32 ± 1·33–2·63 ± 2·35 for 3 mm/1–3%, 1·57 ± 1·36–2·87 ± 2·29 for 2 mm/1–3% and 2·36 ± 1·83–3·58 ± 2·23 for 1 mm/1–3%. Similarly the mean γave ranges: 0·16 ± 0·06–0·19 ± 0·07 for 3 mm/1–3%, 0·21 ± 0·08–0·27 ± 0·10 for 2 mm/1–3% and 0·34 ± 0·14–0·49 ± 0·17 for 1 mm/1–3%. The mean γmax and mean γave increase with increased DTA and increased DD for all low-dose thresholds.

Conclusions:

The establishment of gamma criteria local action levels for SRS/SRT VMAT pre-treatment QA based on institutional resources is imperative as a useful tool for standardising the evaluation of EPID-based patient-specific SRS/SRT VMAT QA. Our data suggest that for intracranial SRS/SRT VMAT QA measured with the EPID, a stricter gamma criterion of 1 mm/2% or 1 mm/3% with ≥90% %GP could be used while still maintaining an in-control QA process with no extra burden on resources and time constraints.

Comprehensive Patient-Specific Intensity-Modulated Radiation Therapy Quality Assurance Comparing Mobius3D/FX to Conventional Methods of Evaluation

Purpose

To determine the appropriateness of implementing Mobius3D/FX (Varian Medical Systems, Inc., Palo Alto, CA, USA) as not only a pretreatment secondary check but as an alternative to measurement-based patient-specific intensity-modulated radiation therapy (IMRT) quality assurance (QA).

Methods

Mobius3D/FX was commissioned and stock beam models were tweaked so that an independent recalculated 3D dose distribution can be obtained. Then, 50 patient-specific treatment plans for various indications were delivered across a 2D ion chamber array, radiochromic film setup, and electronic portal imager and analyzed with MobiusFX and gamma analysis. The concordance of plans scored as passing between MobiusFX and the conventional methods of QA was determined.

Results

All analyzed treatment plans passed with a gamma passing rate >90% across all conventional QA methods, most commonly using a 3%/3mm gamma criterion except for film measurements where a 5%/3mm criterion was applied. There was good agreement and concordance between MobiusFX and conventional methods when using a 3%/3mm criteria for MobiusFX, whereas a 2%/2mm criteria appeared too stringent as it failed treatment plans deemed clinically acceptable using conventional methods.

Conclusions

Using a 50-sample subset of clinically delivered treatment plans this non-inferiority-type comparison shows Mobius3D/FX based on log file analysis to be a suitable alternative to conventional QA methods when utilizing the 3%/3mm gamma criterion. Methods based on log file analysis can provide an opportunity for resource sparing, improving the efficiency, and workflow for evaluating IMRT treatment plans.

An error detection method for real-time EPID-based treatment delivery quality assurance

PURPOSE

To quantify the error detection power of a new treatment delivery error detection method. The method validates monitor unit (MU) resolved beam apertures using real-time EPID images.

METHODS

The on-board EPID imager was used to measure cine-EPID (~10 Hz) images for 27 beams from 15 VMAT/SBRT clinical treatment plans and five nonclinical plans. For each frame acquisition, planned apertures were interpolated from the treatment plan multileaf collimator (MLC) positions expected during the frame acquisition interval. Inaccurate deliveries were identified by monitoring in-aperture missed fluence and out-of-aperture excess fluence beyond a specified buffer. Delivery errors were simulated by perturbing the planned MLC positions before comparison with nonperturbed measured apertures. Systematic 1-5 mm MLC leaf shifts were used to train a logistic regression model to determine the error detection threshold. Model accuracy was monitored using tenfold cross-validation. The model's error detection ability was tested with other error modes: plan control point (CP) weight perturbations, collimator rotations, random MLC leaf position errors, EPID imager shift, and stuck MLC leaf. The error detection accuracy was evaluated using the Matthews correlation coefficient (MCC) and the false positive rate (FPR). Per-beam error thresholds of >1, >5, and >10% errant frames were tested to label per-beam errors. The model also was tested for its ability to distinguish five cases with highly similar plans and compared with gamma analysis.

RESULTS

Delivery errors were detected by monitoring intended per-frame images with a 2 mm MLC buffer. Frame-by-frame aperture errors were identified with an optimal threshold of 0.3% of the expected aperture area. The per-frame FPR was 0.02%. The MCC was 1.00 (perfect classification) for detection based on 1% of frames for random CP weight shift, 3 mm random MLC shifts, 90° and 180° collimator rotations, and an MLC leaf stuck after 10% of the beam delivery. The MCC for 2°, 4°, and 8° collimator rotation were 0.53, 0.76, and 0.96, respectively, for the 1% of beam delivery threshold. The 3 mm EPID shift had poor detection, with a minimum MCC of 0.14. The highly similar plans were reliably detected by the aperture check but were not detectable with gamma analysis.

CONCLUSION

The high error detection sensitivity and low FPR makes the aperture check error detection method well suited to pretreatment and during-treatment beam delivery quality assurance (QA). The aperture check detects subtle beam delivery errors, including those resulting from MLC leaf positioning deviations, CP MU shifts, and stuck MLC leaves. Furthermore, the method can distinguish between highly similar treatment plans. Since the aperture check method monitors for the aperture shapes over a given MU interval, it is also sensitive to errors in MU per CP, without requiring dosimetric calibration of the EPID. The aperture check is one part of a Swiss cheese error detection scheme, which provides redundant error testing of multiple error modes, including nonaperture related errors. The rapid error detection, at 1% of a beam's delivery, make the aperture check a potential candidate for QA of on-line adaptive radiotherapy, or other situations in which pretreatment delivery QA is impractical.

Feasibility of 3D tracking and adaptation of VMAT based on VMAT-CT

BACKGROUND

Local computed tomography (CT) reconstruction is achievable with portal images acquired during volumetric-modulated arc therapy (VMAT) delivery and was named as VMAT-CT. However, the application of VMAT-CT is limited because it has limited field of view and no density information. In addition, the new generation of multi-leaf collimator with faster speed and various collimator angles used in patients' plans could cause more artifacts in VMAT-CT. The goal of this study was to extend VMAT-CT concept, generate complete three-dimensional (3D) CT images, calculate new 3D dose, track and adapt VMAT plan based on updated images and dose.

MATERIALS AND METHODS

VMAT-CT and planning CT of phantoms were fused by rigid or deformable registration to create VMAT-CT+ images. Trackings based on planning CT, VMAT-CT+, and cone beam CT (CBCT) were compared. When prescription dose was not met for planning target volume (PTV), re-planning was demonstrated on an in-house deformable phantom. Possible uncertainties were also evaluated.

RESULTS

Tracking based on VMAT-CT+ was accurate and superior to those based on planning CT and CBCT since VMAT-CT+ can detect changes during treatment. PTV coverage in the deformable phantom decreased after deformations but went up and met the prescription goal after re-planning. The impact of uncertainties on dose was minimal.

CONCLUSION

3D tracking and adaptation of VMAT based on VMAT-CT are feasible. Our study has the potential to increase the confidence of beam delivery, catch and remedy errors during VMAT.

Commissioning of the Mobius3D independent dose verification system for TomoTherapy

In radiation therapy, a secondary independent dose verification is an important component of a quality control system. Mobius3D calculates three‐dimensional (3D) patient dose using reference beam data and a collapsed cone convolution algorithm and analyzes dose‐volume histogram automatically. There are currently no published data on commissioning and determining tolerance levels of Mobius3D for TomoTherapy. To verify the calculation accuracy and adjust the parameters of this system, we compared the measured dose using an ion chamber and film in a phantom with the dose calculated using Mobius3D for nine helical intensity‐modulated radiation therapy plans, each with three nominal field widths. We also compared 126 treatment plans used in our institution to treat prostate, head‐and‐neck, and esophagus tumors based on dose calculations by treatment planning system for given dose indices and 3D gamma passing rates with those produced by Mobius3D. On the basis of these results, we showed that the action and tolerance levels at the average dose for the planning target volume (PTV) at each treatment site are at μ ± 2σ and μ ± 3σ, respectively. After adjusting parameters, the dose difference ratio on average was −0.2 ± 0.6% using ion chamber and gamma passing rate with the criteria of 3% and 3 mm on average was 98.8 ± 1.4% using film. We also established action and tolerance levels for the PTV at the prostate, head‐and‐neck, esophagus, and for the organ at risk at all treatment sites. Mobius3D calculations thus provide an accurate secondary dose verification system that can be commissioned easily and immediately after installation. Before clinical use, the Mobius3D system needs to be commissioned using the treatment plans for patients treated in each institution to determine the calculational accuracy and establish tolerances for each treatment site and dose index.

Improved error detection using a divided treatment plan in volume modulated arc therapy

Aim

We sought to improve error detection ability during volume modulated arc therapy (VMAT) by dividing and evaluating the treatment plan.

Background

VMAT involves moving a beam source delivering radiation to tumor tissue through an arc, which significantly decreases treatment time. Treatment planning for VMAT involves many parameters. Quality assurance before treatment is a major focus of research.

Materials and methods

We used an established VMAT prostate treatment plan and divided it into 12° × 30° sections. In all the sections, only image data that generated errors in one segment and those that were integrally acquired were evaluated by a gamma analysis. This was done with five different patient plans.

Results

The integrated image data resulting from errors in each section was 100% (tolerance 0.5 mm/0.5%) in the gamma analysis result in all image data. Division of the treatment plans produced a shift in the mean value of each gamma analysis in the cranial, left, and ventral directions of 94.59%, 98.83%, 96.58%, and the discrimination ability improved.

Conclusion

The error discrimination ability was improved by dividing and verifying the portal imaging.

Improving accuracy for stereotactic body radiotherapy treatments of spinal metastases

PURPOSE

Use of SBRT techniques is now a relatively common recourse for spinal metastases due to good local control rates and durable pain control. However, the technique has not yet reached maturity for gantry-based systems, so work is still required in finding planning approaches that produce optimum conformity as well as delivery for the slew of treatment planning systems and treatment machines.

METHODS

A set of 32 SBRT spine treatment plans based on four vertebral sites, varying in modality and number of control points, were created in Pinnacle. These plans were assessed according to complexity metrics and planning objectives as well as undergoing treatment delivery QA on an Elekta VersaHD through ion chamber measurement, ArcCheck, film-dose map comparison and MLC log-file reconstruction via PerFraction.

RESULTS

All methods of QA demonstrated statistically significant agreement with each other (r = 0.63, P < 0.001). Plan complexity and delivery accuracy were found to be independent of MUs (r = 0.22, P > 0.05) but improved with the number of control points (r = 0.46, P < 0.03); with use of 90 control points producing the most complex and least accurate plans. The fraction of small apertures used in treatment had no impact on plan quality or accuracy (r = 0.29, P > 0.05) but rather more complexly modulated plans showed poorer results due to MLC leaf position inaccuracies. Plans utilizing 180 and 240 control points produced optimal plan coverage with similar complexity metrics to each other. However, plans with 240 control points demonstrated slightly better delivery accuracy, with fewer MLC leaf position discrepancies.

CONCLUSION

In contrast to other studies, MU had no effect on delivery accuracy, with the most impactful parameter at the disposal of the planner being the number of control points utilized.

Evaluation of machine log files/MC-based treatment planning and delivery QA as compared to ArcCHECK QA

PURPOSE

A treatment planning/delivery QA tool using linac log files (LF) and Monte Carlo (MC) dose calculation is investigated as a standalone alternative to phantom-based patient-specific QA (ArcCHECK (AC)).

METHODS

Delivering a variety of fields onto MapCHECK2 and ArcCHECK, diode sensitivity dependence on dose rate (in-field) and energy (primarily out-of-field) was quantified. AC and LF QAs were analyzed with respect to delivery complexity by delivering 12 × 12 cm static fields/arcs comprised of varying numbers of abutting sub-fields onto ArcCHECK. About 11 clinical dual-arc VMAT patients planned using Pinnacle's convolution-superposition (CS) were delivered on ArcCHECK and log file dose (LF-CS and LF-MC) calculated. To minimize calculation time, reduced LF-CS sampling (1/2/3/4° control point spacing) was investigated. Planned ("Plan") and LF-reconstructed CS and MC doses were compared with each other and AC measurement via statistical [mean ± StdDev(σ)] and gamma analyses to isolate dosimetric uncertainties and quantify the relative accuracies of AC QA and MC-based LF QA.

RESULTS

Calculation and ArcCHECK measurement differed by up to 1.5% in-field due to variation in dose rate and up to 5% out-of-field. For the experimental segment-varying plans, despite CS calculation deviating by as much as 13% from measurement, Plan-MC and LF-MC doses generally matched AC measurement within 3%. Utilizing 1° control point spacing, 2%/2 mm LF-CS vs AC pass rates (97%) were slightly lower than Plan-CS vs AC pass rates (97.5%). Utilizing all log file samples, 2%/2 mm LF-MC vs AC pass rates (97.3%) were higher than Plan-MC vs AC (96.5%). Phantom-dependent, calculation algorithm-dependent (MC vs CS), and delivery error-dependent dose uncertainties were 0.8 ± 1.2%, 0.2 ± 1.1%, and 0.1 ± 0.9% respectively.

CONCLUSION

Reconstructing every log file sample with no increase in computational cost, MC-based LF QA is faster and more accurate than CS-based LF QA. Offering similar dosimetric accuracy compared to AC measurement, MC-based log files can be used for treatment planning QA.

A clinically relevant IMRT QA workflow: Design and validation

PURPOSE

The purpose of this study was to determine clinically relevant pass/question/fail criteria for gamma analysis of intensity-modulated radiation therapy quality assurance (IMRT QA) plans, identify which plans should be further analyzed with dose-volume histogram (DVH) metrics, and create a workflow for performing that DVH-based analysis.

METHODS

A total of 11 plans, 5 prostate and 6 head/neck, were selected to represent known good plans based on their high-passing rate using conventional IMRT QA criteria. These were modified by moving the programmed MLC positions to underdose the target or overdose important structures by varying amounts. Commercially available hardware/software was used to measure and analyze all plans (76 total) using 4%/3 mm, 3%/3 mm, 3%/2 mm, and 2%/2 mm gamma criteria. Two receiver operator characteristic (ROC) curves per criterion were created to assess effective passing rates. One ROC curve was to find a higher threshold that determined a clear pass and the second to find a lower threshold to determine a clear failure. Plans between these two thresholds need DVH-based analysis to assess the clinical consequence of the dose difference. The modified plans were analyzed in the planning system and reconstructed in commercially available DVH-based analysis software to access the accuracy and usefulness of the software.

RESULTS

Analysis of the ROC curves showed optimal pass and fail thresholds for plan error detection per criterion to achieve clinically relevant sensitivity and specificity. Based on measurement uncertainty and pass/fail ranges, 3%/2 mm gamma criteria with a pass threshold of 95% and a fail threshold of 90% were most optimal. DVH analysis showed good agreement with all reconstructed plans except where the changes to the MLC patterns caused the periphery of the target to be underdosed. For questionable plans, comparing the organ-specific DVHs to the physician-provided planning constraints proved to be an efficient and effective workflow since plans for which the target dose was slightly high or where organs at risk were underdosed could be released for the treatment without consulting the physician for a clinical decision.

CONCLUSION

This work indicates the potential for appreciable improvement in error detection for IMRT QA. Using effective pass/fail thresholds to determine plans that need DVH-based analysis minimizes the need for excessive, time-consuming, analysis, and making use of the dosimetric constraints of the plan minimizes the burden on physicians. Overall, DVH-based analysis is a powerful tool that can provide substantial insight over the traditional approach that does not provide structure-specific data.

Dosimetric evaluation of MobiusFX in the RapidArc delivery quality assurance comparing with 3DVH

The dosimetric characteristics of MobiusFX, which uses the treatment machine log file to calculate the dose inside the patient body, were analyzed for use in the RapidArc delivery quality assurance (DQA) process. The accuracy and usefulness of MobiusFX in clinical cases was evaluated by comparing the dose calculated by MobiusFX with that calculated by the conventional measurement dose based program, 3DVH. The results of gamma evaluation with three different criteria (3%–3 mm, 4%–3 mm, 5%–3 mm) were analyzed, and the dose changes were calculated while simulating variable position errors (6 mm, 3 mm) and dosimetric output increases (6%, 3%). Although the doses calculated by each tool were not identical due to differences in the calculation algorithms, the doses calculated by MobiusFX were generally similar to those calculated by 3DVH. Based on these results, MobiusFX exhibited the required accuracy for clinical application. However, it could not determine the dosimetric output variation. It should therefore be considered a supplementary DQA tool that can verify the error in the daily treatment process, but not an ideal DQA tool that can replace conventional measurement based DQA methods.

Investigation of a real-time EPID-based patient dose monitoring safety system using site-specific control limits

Purpose

The aim of this study is to investigate the performance and limitations of a real-time transit electronic portal imaging device (EPID) dosimetry system for error detection during dynamic intensity modulated radiation therapy (IMRT) treatment delivery. Sites studied are prostate, head and neck (HN), and rectal cancer treatments.

Methods

The system compares measured cumulative transit EPID image frames with predicted cumulative image frames in real-time during treatment using a χ comparison with 4 %, 4 mm criteria. The treatment site-specific thresholds (prostate, HN and rectum IMRT) were determined using initial data collected from 137 patients (274 measured treatment fractions) and a statistical process control methodology. These thresholds were then applied to data from 15 selected patients including 5 prostate, 5 HN, and 5 rectum IMRT treatments for system evaluation and classification of error sources.

Results

Clinical demonstration of real-time transit EPID dosimetry in IMRT was presented. For error simulation, the system could detect gross errors (i.e. wrong patient, wrong plan, wrong gantry angle) immediately after EPID stabilisation; 2 seconds after the start of treatment. The average rate of error detection was 7.0 % (prostate = 5.6 %, HN= 8.7 % and rectum = 6.7 %). The detected errors were classified as either clinical in origin (e.g. patient anatomical changes), or non-clinical in origin (e.g. detection system errors). Classified errors were 3.2 % clinical and 3.9 % non-clinical.

Conclusion

An EPID-based real-time error detection method for treatment verification during dynamic IMRT has been developed and tested for its performance and limitations. The system is able to detect gross errors in real-time, however improvement in system robustness is required to reduce the non-clinical sources of error detection.

Comparison between Dual Arc VMAT and 7F-IMRT in the protection of hippocampus for patients during whole brain radiotherapy

PURPOSE

The purpose of this study was to compare the dosimetric characteristics for protection of the hippocampus between dual arc VMAT (volumetric modulated arc therapy) and 7 fields intensity-modulated radiation therapy (7F-IMRT) for patients with brain metastases from lung cancer under the whole brain radiotherapy.

METHODS

Based on ten cases with brain metastases from lung cancer, two types of radiotherapy plans were designed, namely, dual arc VMAT and 7F-IMRT. Provided that the clinical requirements were satisfied, the comparisons of target dose distribution, conformity index (CI), homogeneity index (HI), dose of organs at risk (OARs), monitor units (MU) and treatment time between dual arc VMAT and 7F-IMRT were investigated for their dosimetric difference.

RESULTS

Both treatment plans met the requirements of clinical treatments. However, the PTV-HA conformity and homogeneity of dual arc VMAT were superior to those of 7F-IMRT (P < 0.05). As to OARs, the mean maximum doses (Dmax) of hippocampus, eyes and optic nerves in the dual arc VMAT plan were all lower than those in 7F-IMRT plan (P < 0.05), but the result had no statistical significance (P < 0.05) for the maximum dose of lens. Compared with 7F-IMRT, dual arc VMAT reduced the average number of MU by 67% and the average treatment time by 74%. Therefore, treatment time was shortened by dual arc VMAT.

CONCLUSION

With regards to the patients with brain metastases from lung cancer under the whole brain radiotherapy, the PTV-HA conformity and homogeneity of dual arc VMAT were superior to those of 7F-IMRT under the precise of meeting the clinical requirements. In addition, dual arc VMAT remarkably reduced the irradiation dose to OARs (hippocampus, eyes and optic nerves), MU and treatment time, as well, guaranteed patients with better protection.